If Mammalian Target of Metformin Indirectly Is Mammalian Target of Rapamycin, Then the Insulin-Like Growth Factor-1 Receptor Axis Will Audit the Efficacy of Metformin in Cancer Clinical Trials
- 20 November 2009
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (33) , e207-e209
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- Metformin in Breast Cancer: Time for ActionJournal of Clinical Oncology, 2009
- Metformin induces unique biological and molecular responses in triple negative breast cancer cellsCell Cycle, 2009
- Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitroCell Cycle, 2009
- Is it Time to Test Metformin in Breast Cancer Clinical Trials?Cancer Epidemiology, Biomarkers & Prevention, 2009
- The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathyAnnals of Oncology, 2009
- The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cellsCell Cycle, 2009
- Targeting AMPK: A new therapeutic opportunity in breast cancerCritical Reviews in Oncology/Hematology, 2008
- Activation of AMPK is necessary for killing cancer cells and sparing cardiac cellsCell Cycle, 2008
- Metformin Inhibits Mammalian Target of Rapamycin–Dependent Translation Initiation in Breast Cancer CellsCancer Research, 2007